VistaGen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended June 30, 2016; comparative income and cash-flow period ended June 30, 2015. The filing was dated August 12, 2016.
Business context and outlook
VistaGen is a clinical-stage biopharmaceutical company with no commercial products or current revenue. Its lead candidate, oral AV-101, is in Phase 2 development for treatment-resistant major depressive disorder (MDD). The NIMH-funded Phase 2a study began dosing in November 2015. The company also described early drug-rescue and regenerative-medicine work using its stem-cell technology platform.
Management anticipated Phase 2a topline results in Q2 2017 and planned to begin a company-led Phase 2b MDD study at the end of Q4 2016, with topline results anticipated in Q2 2018. These are forward-looking expectations, not assured outcomes.
Financial results and liquidity
| Metric | Three months ended June 30, 2016 | Three months ended June 30, 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $825,700 | $372,600 |
| General and administrative expense | $1,137,600 | $1,448,500 |
| Total operating expenses | $1,963,300 | $1,821,100 |
| Net loss | $1,967,100 | $29,524,100 |
| Net loss attributable to common stockholders | $2,618,000 | $29,993,600 |
| Basic and diluted loss per common share | $0.51 | $19.23 |
| Net cash used in operating activities | $1,671,000 | $823,300 |
There is no meaningful revenue or gross-margin comparison because the company reported no revenue. R&D spending more than doubled, principally reflecting AV-101 development and patent-related costs. G&A fell, mainly because the prior-year period included larger noncash professional-service and warrant-modification expenses.
Cash and cash equivalents were $8.50 million at June 30, 2016, versus $428,500 at March 31, 2016. Financing activities provided $9.74 million, including approximately $9.5 million net proceeds from a May public offering and $278,000 from Series B preferred-unit sales. Operating activities used $1.67 million and investing activities used $2,000.
Total liabilities were $2.60 million and stockholders’ equity was $6.16 million at June 30, compared with liabilities of $3.97 million and a stockholders’ deficit of $2.98 million at March 31. Notes payable were $105,900, all current; this was principally an insurance-premium financing note. The company had $946,000 of accrued Series B preferred dividends recorded as a non-current liability. Accumulated deficit was $133.7 million.
Material changes, financing and risks
- The prior-year net loss included a $25.05 million noncash loss on extinguishment of debt and $1.89 million noncash warrant-liability expense. Their absence in 2016 explains most of the year-over-year reduction in reported net loss; operating loss increased instead.
- The May 2016 public offering issued 2,570,040 common shares and warrants for up to 2,705,883 shares, raising about $9.5 million net. The company’s common stock began trading on Nasdaq in May. Series B preferred conversions and dividend settlements also resulted in substantial common-share issuance.
- At June 30, 4,606,480 warrants to purchase common shares were outstanding. Potential dilution also included preferred stock and options; the filing reported 9,909,219 potentially dilutive securities excluded from diluted loss per share as antidilutive.
- Management expected available proceeds to support operations through fiscal year-end March 31, 2017, but said they would not fund completion of the Phase 2b study. Assuming no exercise of the public-offering warrants or underwriters’ additional-share option, the company estimated it would need another $10–$12 million before the end of Q2 2017 to complete that study.
- The filing states that recurring losses and negative operating cash flow create substantial financing needs. Additional capital may not be available on acceptable terms or at all; failure to obtain it could force reductions, delays or discontinuation of R&D and could threaten the company’s ability to continue as a going concern. Financial statements were prepared on a going-concern basis and did not include adjustments for this uncertainty.
- Key business risks include AV-101 trial efficacy, safety and timing; FDA and other regulatory requirements; reliance on the NIMH, CROs and contract manufacturers; competition; limited patent protection (the company reported no issued patents covering AV-101); and further dilution or restrictive financing terms. Management reported effective disclosure controls and no material change in internal control over financial reporting. No legal proceedings or material subsequent events were reported.
Most important facts for investors to verify
- Whether the Phase 2a and Phase 2b studies meet the stated enrollment, launch and results timelines, and whether trial results support continued development.
- Cash burn and remaining runway against the company’s stated need for $10–$12 million to complete Phase 2b; actual availability and terms of future financing.
- Potential dilution from outstanding warrants, preferred-stock conversion rights, options and any additional securities issuance.
- Whether R&D costs rise as the company advances AV-101, and whether the NIMH continues to fund the Phase 2a study as described.
- The status and scope of AV-101 intellectual-property protection, manufacturing readiness and regulatory requirements.